Catalent Shares Jump As Investors Cheer Revised, Better Than Expected FY22 Outlook

  • Catalent Inc CTLT reported Q3 FY22 sales of $1.27 billion, +21% Y/Y as reported, or 23% in constant currency, edging out analysts' average expectation of $1.22 billion.
  • Adjusted EPS of $1.04, compared to $0.82 last year, surpassed the consensus of $0.94.
  • Adjusted EBITDA was $339 million, or a margin of 27%, compared to $274 million (26%) a year ago.
  • Biologics segment sales increased 30% cc to $698 million.
  • Softgel and Oral Technologies segment revenues of $324 million were up 37% cc.
  • The Oral and Specialty Delivery segment's sales were $154 million, a decrease of 8% cc.
  • Clinical Supply Services segment revenues improved 3% cc to $101 million.
  • Guidance: For FY22, Catalent expects revenue of $4.8 billion - $4.9 billion, better than the prior outlook of $4.74 billion - $4.86 billion and the consensus of $4.8 billion.
  • It expects adjusted EBITDA of 1.265 billion - $1.305 billion, compared to $1.25 billion - $1.30 billion expected earlier.
  • The Company forecasts an adjusted net income of $665 million - $705 million, better than the $650 million - $700 million anticipated earlier.
  • Price Action: CTLT shares are up 11.8% at $100.78 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLarge CapNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!